ALX Oncology Holdings Inc reports results for the quarter ended in September - Earnings Summary

ALX Oncology Holdings

09/11/2022 11:59

* ALX Oncology Holdings Inc  ALXO.OQ  reported a quarterly
adjusted loss of 87 cents​​ per share for the quarter ended in
September. The mean expectation of seven analysts for the
quarter was for a loss of 77 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * ALX Oncology Holdings Inc's reported EPS for the quarter
was a
loss of 87 cents​.
    * The mean earnings estimate of analysts had risen by
about 0.9%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * ALX Oncology Holdings Inc shares had risen by 30.6% this
quarter and lost 41.8% so far this year.
    * The company reported a quarterly loss of $35.32 million.
    * Wall Street's median 12-month price target for ALX
Oncology
Holdings Inc is $35.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
9 at 11:59 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.77          -0.87          Missed
 Jun. 30 2022      -0.63          -0.81          Missed
 Mar. 31 2022      -0.71          -0.60          Beat
 Dec. 31 2021      -0.62          -0.70          Missed